This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Data availability
The datasets generated and analyzed during the current study are available from the corresponding author upon reasonable request.
References
Valtis YK, Flamand Y, Shimony S, Place AE, Silverman LB, Vrooman LM, et al. Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols. Leukemia. 2024. https://doi.org/10.1038/s41375-023-02115-4.
Storring JM, Minden MD, Kao S, Gupta V, Schuh AC, Schimmer AD, et al. Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. Br J Haematol. 2009;146:76–85. https://doi.org/10.1111/j.1365-2141.2009.07712.x.
Martell MP, Atenafu EG, Minden MD, Schuh AC, Yee KW, Schimmer AD, et al. Treatment of elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol. Br J Haematol. 2013;163:458–64. https://doi.org/10.1111/bjh.12561.
DeAngelo DJ, Stevenson KE, Dahlberg SE, Silverman LB, Couban S, Supko JG, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015;29:526–34. https://doi.org/10.1038/leu.2014.229.
Moreno M, Wolfe A, Dara C, Yee KW. Schuh AC, Longitudinal therapeutic drug monitoring to optimize pegaspargase dosing in adults with acute lymphoblastic leukemia (All). EHA Congress 2022; Abstract: EP407: 2020.
Advani AS, Larsen E, Laumann K, Luger SM, Liedtke M, Devidas M, et al. Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. Blood Adv. 2021;5:504–12. https://doi.org/10.1182/bloodadvances.2020002439.
Author information
Authors and Affiliations
Contributions
MAP, AC, AS, and HS contributed to the conceptualization and design. MAP, AS and HS contributed to data analysis, interpretation, and writing of the manuscript. EGA contributed to data analysis. MAP, JAL, JS, SAH, and SWL contributed to data collection. VG, MD, SA, YK, BA, DM, GRC, CS, ADS, MM, and HS contributed to essential data and manuscript revision. All authors approved the submitted and final version.
Corresponding author
Ethics declarations
Competing interests
This study has not been funded by any pharmaceutical companies. There were no direct COI specifically related to this research project. ADS has received research funding from Takeda Pharmaceuticals, BMS, and Medivir AB, and consulting fees/honorarium from Takeda, Novartis, Jazz, and Otsuka Pharmaceuticals. ADS is named on a patent application for the use of DNT cells to treat AML. ADS is a member of the Medical and Scientific Advisory Board of the Leukemia and Lymphoma Society of Canada.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Perusini, M.A., Andrews, C., Eshetu, A.G. et al. Asparaginase completion among adults including older patients with acute lymphoblastic leukemia treated with a modified DFCI protocol. Leukemia 38, 912–913 (2024). https://doi.org/10.1038/s41375-024-02201-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-024-02201-1